Screening compounds against HCV based on MAVS/IFN-β pathway in a replicon model

World Journal of Gastroenterology

Volumn 16, Issue 44, 2010, Pages 5582-5587

  Fu, Qiu Xia ^a   Wang, Li Cui ^a   Jia, Shuai Zheng ^a   Gao, Bo ^a   Zhou, Yong ^a   Du, Juan ^a   Wang, Ying Li ^a   Wang, Xiao Hui ^a   Peng, Jian Chun ^a   Zhan, Lin Sheng ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Drug screening; Hepatitis C virus; Interferon ; Mitochondrial antiviral signaling protein

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; ALPHA INTERFERON; BETA INTERFERON; CYCLOSPORIN A; MITOCHONDRIAL PROTEIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; VIRUS PROTEIN; YELLOW FLUORESCENT PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL LEVEL; CELLULAR DISTRIBUTION; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVITY; ENZYME RELEASE; FLUORESCENCE MICROSCOPY; HEPATITIS C VIRUS; INTERFERON PRODUCTION; MITOCHONDRION; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RECEPTOR DOWN REGULATION; REPLICON; SCREENING TEST; VIRUS DETECTION; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 78649718782     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i44.5582     Document Type: Article

References (31)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562
2. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-1696
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567
4. Husa P, Husova L. Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons. Bratisl Lek Listy 2001; 102: 248-252
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
6. De Francesco R, Carfí A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev 2007; 59: 1242-1262
7. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNAdependent RNA polymerase. Antiviral Res 2003; 58: 1-16
8. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463
9. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19
10. Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993; 67: 4017-4026
11. Baril M, Racine ME, Penin F, Lamarre D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol 2009; 83: 1299-1311
12. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DT, Weinman SA, Lemon SM, Gale M Jr. Viral and therapeutic control of IFNbeta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006; 103: 6001-6006
13. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939-945
14. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, Gale M Jr. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-1148
15. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Tolllike receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102: 2992-2997
16. Kumar H, Kawai T, Kato H, Sato S, Takahashi K, Coban C, Yamamoto M, Uematsu S, Ishii KJ, Takeuchi O, Akira S. Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med 2006; 203: 1795-1803
17. Ciesek S, Steinmann E, Wedemeyer H, Manns MP, Neyts J, Tautz N, Madan V, Bartenschlager R, von Hahn T, Pietschmann T. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 2009; 50: 1638-1645
18. Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for antihepatitis C virus strategy. Rev Med Virol 2007; 17: 245-252
19. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, Kurosaki M, Maekawa S, Yamashiro T, Chen CH, Itsui Y, Kakinuma S, Watanabe M. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313: 42-47
20. Bartenschlager R, Kaul A, Sparacio S. Replication of the hepatitis C virus in cell culture. Antiviral Res 2003; 60: 91-102
21. Boonstra A, van der Laan LJ, Vanwolleghem T, Janssen HL. Experimental models for hepatitis C viral infection. Hepatology 2009; 50: 1646-1655
22. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113
23. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, Lanford RE, Feinstone SM, Major ME, Leroux-Roels G, Rice CM. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 2006; 103: 3805-3809
24. Liu C. Hepatitis C virus: virology and experimental systems. Clin Liver Dis 2006; 10: 773-791
25. Horscroft N, Lai VC, Cheney W, Yao N, Wu JZ, Hong Z, Zhong W. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir Chem Chemother 2005; 16: 1-12
26. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102: 9294-9299
27. Zhang Y, Weady P, Duggal R, Hao W. Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening. Antimicrob Agents Chemother 2008; 52: 666-674
28. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006; 80: 5308-5320
29. Hao W, Herlihy KJ, Zhang NJ, Fuhrman SA, Doan C, Patick AK, Duggal R. Development of a novel dicistronic reporterselectable hepatitis C virus replicon suitable for highthroughput inhibitor screening. Antimicrob Agents Chemother 2007; 51: 95-102
30. Moradpour D, Evans MJ, Gosert R, Yuan Z, Blum HE, Goff SP, Lindenbach BD, Rice CM. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol 2004; 78: 7400-7409
31. Jones DM, Gretton SN, McLauchlan J, Targett-Adams P. Mobility analysis of an NS5A-GFP fusion protein in cells actively replicating hepatitis C virus subgenomic RNA. J Gen Virol 2007; 88: 470-475